From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement
FROM THE EDITOR

Welcome to the Graft-vs.-Host Disease Resource Center! Here you will find updated information, education, and other resources from the field of GVHD. We're excited to provide this offering to you and your colleagues. Take a look around, and send us your feedback to jadpro-editor@broadcastmed.com.

Jaime Shahan, MPAS, PA-C                                        Physician Assistant, Hematology/ Oncology Simmons Comprehensive Cancer Center at Redbird, University of Texas Southwestern  

News & Literature Highlights

Bone Marrow Transplantation

Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Transplantation and Cellular Therapy

Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation

Bone Marrow Transplantation

Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor

Bone Marrow Transplantation

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

Transplantation Proceedings

Clinical and economic burden associated with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in Germany

Bone Marrow Transplantation

Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study

PLOS One

The effect of oral chronic graft-versus-host disease on bodyweight: A cohort study

Advances in Hematology

Novel pharmacological treatment options of steroid-refractory graft-versus-host disease

Clinical Cancer Research

Targeting hedgehog signaling with glasdegib in patients with refractory sclerotic chronic GVHD: A report of two phase I/II trials

2023 American Society of Hematology Annual Meeting Abstract

Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201)

Advertisement
Advertisement